Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Yang

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Cardiovascular Research|August 2, 2005
The cAMP response element binding protein modulates expression of the transient outward current: implications for cardiac memoryKornelis W Patberg, Maria N Obreztchikova, Sarah F Giardina, et al.
Haematologica|March 14, 2020
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemiaXinyu Li, Yongwei Su, Katie Hege, et al.
Clinical and Translational Science|December 24, 2022
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Pinkal Desai, Nikki Daskalakis, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AMLMd Hafiz Uddin, Sandhya Dhiman, Yufen Han, et al.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
Molecular Oncology|September 16, 2025
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidineShuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Circulation Research|January 24, 2012
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunctionNhat-Tu Le, Yuichiro Takei, Tetsuro Shishido, et al.
The Pediatric Infectious Disease Journal|March 30, 2013
Clinical features and genetic analysis of Taiwanese patients with the hyper IgM syndrome phenotypeWen-I Lee, Jing-Long Huang, Kuo-Wei Yeh, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Cardiovascular Research|August 2, 2005
The cAMP response element binding protein modulates expression of the transient outward current: implications for cardiac memoryKornelis W Patberg, Maria N Obreztchikova, Sarah F Giardina, et al.
Haematologica|March 14, 2020
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemiaXinyu Li, Yongwei Su, Katie Hege, et al.
Clinical and Translational Science|December 24, 2022
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Pinkal Desai, Nikki Daskalakis, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AMLMd Hafiz Uddin, Sandhya Dhiman, Yufen Han, et al.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
Molecular Oncology|September 16, 2025
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidineShuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Circulation Research|January 24, 2012
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunctionNhat-Tu Le, Yuichiro Takei, Tetsuro Shishido, et al.
The Pediatric Infectious Disease Journal|March 30, 2013
Clinical features and genetic analysis of Taiwanese patients with the hyper IgM syndrome phenotypeWen-I Lee, Jing-Long Huang, Kuo-Wei Yeh, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Pageof 15